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Background: The mechanism for the increased risk of head and neck cancer (HNC) observed 
in HIV patients is controversial. We hypothesized that family-related risk factors increase the 
risk of HNC why we estimated the risk of this type of cancer in both HIV patients and their 
parents.
Methods: We estimated the cumulative incidence and incidence rate ratios (IRRs) of HNC 
in 1) a population of all Danish HIV patients identified from the Danish HIV Cohort Study 
(n = 5053) and a cohort of population controls matched on age and gender (n = 50,530) (study 
period; 1995–2009) and 2) the parents of HIV patients and population controls (study period 
1978–2009). To assess the possible impact of human papilloma virus (HPV)–associated cancers, 
the sites of squamous cell HNCs were categorized as HPV related, potentially HPV related, and 
potentially HPV unrelated.
Results: Seventeen (0.3%) HIV patients vs 80 (0.2%) population controls were diagnosed 
with HNC cancer in the observation period. HIV patients had an increased risk of HNC (IRR 
3.05 [95% CI 1.81–5.15]). The IRR was considerably increased in HIV patients older than 
50 years (adjusted IRR; 4.58 [95% CI 2.24–9.35]), diagnosed after 1995 (adjusted IRR 6.31 
[95% CI 2.82–14.08]), previous or current smoker (adjusted IRR 4.51 [95% CI 2.47–8.23]), 
with baseline CD4 count 350 cells/µL (adjusted IRR; 3.89 [95% CI 1.95–7.78]), and men 
heterosexually infected with HIV (adjusted IRR 5.54 [95% CI 1.96–15.66]). Fifteen (83%) of 
the HIV patients diagnosed with HNC were current or former smokers. The IRR of squamous 
cell HNC in HIV patients was high at HPV-relate sites, potentially HPV-related sites, and 
potentially HPV-unrelated sites. Both fathers and mothers of HIV patients had an increased 
risk of HNC (adjusted IRR for fathers 1.78 [95% CI 1.28–2.48], adjusted IRR for mothers 
2.07 [95% CI 1.05–4.09]).
Conclusion: HIV appears to be a marker of behavioral or family-related risk factors that affect 
the incidence of HNC in HIV patients.
Keywords: HIV, head and neck cancer incidence, matched cohort, population controls, 
parents
Introduction
After the introduction of highly active antiretroviral therapy (HAART) HIV has changed 
from a fatal disease to a chronic condition and well-treated HIV patients now have an 
overall life expectancy close to that of non-HIV patients.1 Due to immunological recovery, 
there has been a remarkable decline in AIDS-defining cancers, whereas the increased 
risk of certain non-AIDS-defining cancers, including head and neck cancer (HNC), has 
persisted in the HIV population.2–5 Besides alcohol consumption and smoking, risk of 
HNC has been associated with infection with human papilloma virus (HPV).6–10 The Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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exact mechanism behind the increased risk of HNC in HIV 
patients is unclear.
We hypothesized that family-related risk factors may 
partly explain the increased risk of HNC observed in HIV 
patients. We therefore performed a national cohort study to 
compare the risk of HNC in Danish HIV patients and their 
parents with that of matched cohorts from the background 
population.
Methods
In this study we estimate the risk of HNC in 1) HIV patients 
compared with population controls matched on age and 
gender and 2) in the parents of the HIV patients compared 
with the parents of the population controls.
setting
Denmark had a population of 5.5 million as of 31 December 
2008, with an estimated HIV prevalence of approximately 
0.09% in the adult population.
Data sources
We used the unique 10-digit civil registration number 
assigned to all individuals in Denmark at birth or on 
immigration to link the data sources described below.11
The Danish HIV Cohort study (DHCS) is a population-
based prospective nationwide cohort study of all HIV patients 
16 years or older at diagnosis and who are treated at Danish 
HIV centers after 1 January 1995. Patients are consecutively 
enrolled, and multiple registrations are avoided through the 
use of the unique civil registration number. Data are updated 
yearly and include demographics, data on smoking, date of 
HIV infection, route of HIV infection, AIDS-defining events, 
date and cause of death, and antiretroviral treatment. CD4+ 
cell counts and HIV-RNA measurements are extracted elec-
tronically from laboratory data files. The study is described 
in detail elsewhere.12 Patients who were registered at least 
once as consuming tobacco in any quantity were considered 
smokers.
Population controls and parents of both HIV patients and 
population controls were identified from the Danish Civil 
Registration System (DCRS). The DCRS was established 
in 1968 and stores information of vital status, residency 
as well as immigration and emigration on all Danish   
residents.11
Data on all cancers were obtained from the Danish Cancer 
Registry. The Danish Cancer Register is a population-based 
register and contains information on all incident cancers 
diagnosed in Danish Citizens since 1943.13
Data on smoking are not available in the Danish national 
registries.
study populations
hiV and population controls
In the first part of the study, we included all HIV patients 
from the Danish HIV Cohort Study assigned a Danish civil 
registration number and not diagnosis with cancer prior 
to index date (see Figure 1). The index date was defined 
as 1 January 1995, the date of the HIV diagnosis, or date 
of immigration, whichever came last. For each of the HIV 
patients we identified 10 age- and gender-matched popula-
tion control subjects from the DCRS who were alive and 
living in Denmark at the index date of the corresponding HIV 
patient (referred to also as the index date of the respective 
population controls) and not diagnosed with a cancer prior 
to index date.
Parents
Over time, inclusion of parents’ civil registration numbers 
in the DCRS has increased from ,10% for individuals born 
before 1952, to 43% for the 1952 birth cohort, to 96% for the 
1959 birth cohort, and to 99% for persons born after 1970.14 
Consistent with this trend, we found that 8% of individuals 
born before 1952 had registered parents. HNCs have been 
classified by both topography and histological type since 
1978. Thus, to reduce selection bias we included parents of 
HIV patients/population controls who 1) gave birth to an HIV 
patient/population control individual after 1 January 1952,   
2) were alive and living in Denmark after 1 January 1978, 
3) were not diagnosed with cancer prior to the parent index 
date, and 4) reached the age of 40 years in the study period 
(see Figure 1). In order to make the parent populations more 
homogenous in terms of age and risk, observation did not 
start until date of the fortieth birthday. In summary, the parent 
index date was defined as 1 January 1978, date of birth of the 
included HIV patient or population control, the date of the 
fortieth birthday, or date of registration in DCRS, whichever 
came last. In case a parent was the father or mother of both 
an HIV patient and a population control, they were included 
in both parent populations.
Outcome
In the first study, outcome was time to first diagnosis of 
HNC. All primary cancers were identified using NORDCAN 
definitions15 (see Appendix). HNC was defined as the 
following ICD-10 codes: C00–C14, C30–C32. Lymphomas 
and nonmicroscopically confirmed malignancies in the head Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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neck region were not considered HNCs. Further, we divided 
all HNCs of squamous cell origin (ICD-O-3 morphology 
codes 8050–8084, 8120–8131) into three groups: HPV 
related, potentially HPV related, and potentially HPV unre-
lated. The three groups are based on the classification made 
by Ryerson et al16 and categorized by the following ICD-1O 
codes – 1) HPV-associated: Tonsils including Waldeyers 
ring (C09, C14.2), Base of tongue and lingual tonsil (C01.9, 
C02.4), Other oro-  pharyngeal sites (C02.8, C10.2, C10.8.0, 
C10.9, C14.0, C14.8); 2) Potentially HPV-associated: 
Tongue (C02.0–C02.3, C02.9), Other oral cavity sites (C03, 
C04, C05.0, C06), Larynx (C32), Other oro-pharyngeal 
sites (C05.1, C05.2, C05.8, C05.9, C10.0, C10.1, C10.3); 
and 3) Potentially unrelated to HPV: Remaining HNC sites 
(C00, C07, C08, C10.4, C11–C13, C14.1, C30, C31). The 
potentially HPV-related cancers are based on the anatomi-
cal similarity to the HPV-related cancers in the first group, 
even though an association with HPV has not yet been 
established.
statistics
Differences in characteristics between groups were evalu-
ated by the χ2 test/Fischer’s exact test and Kruskal–Wallis 
test when appropriate.
c
5,168 adult HIV patients in The Danish HIV Cohort Study seen
in one of the eight centres before 1 January 2009
5,053 HIV patients included
2,317 fathers of HIV
patients included
50,530 population controls included 
2,502 mothers of HIV
patients included
30,886 fathers of
population control
included
31,928 mothers of
population controls
included
HIV: control population ratio = 1:10
115 HIV patients excluded 
due to a diagnosis of cancer
before index date 
Excluded parents of
HIV patients:
Excluded because
offspring was born before
1 January 1952:  
Not traceable and
excluded:
Fathers and mothers of
HIV infected siblings
(only count once):
Excluded because the
parent was not alive or
did not have residency in
DK after 1 January 1978:
Excluded due to cancer
diagnosis before index
date:
Did not reach the age of
40 years in the study
period and were excluded:
5,053 fathers of
HIV patients
5,053 mothers of
HIV patients
1,047 
(20.7%) 
1,558 
(30.8%)
15
(0.3%)
109  
(2.2%) 
7
(0.1%)
1,047 
(20.7%) 
1,387 
(27.4%) 
17
(0.3%)
57 
(0.1%) 
42
(0.2%)
Excluded parents of
population controls:
Excluded because
offspring was born before
1 January 1952:
Not traceable and
excluded:
Fathers and mothers of
population control
siblings (only count once):
Excluded because the
parent was not alive or
did not have residency in
DK after 1 January 1978:
Excluded due to cancer
diagnosis before index
date:
Did not reach the age of
40 years in the study
period and were excluded:
10,470  
(79.3%) 
7,589 
(15.0)
446
(0.9%)
160
(0.3%)
979
(1.9%)
10,470 
(79.3%)
6,822 
(13.5%)
437
(0.9%)
489
(1.0%)
381
(0.8%)
50,530 fathers of
population controls
50,530 mothers of
population controls
0
(0%)
1
(<0.1%)
0
(0%)
3
(<0.1%)
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We estimated the probability of HNC and the relative risk of 
HNC in all study populations. Observation time was calculated 
from the respective index date to date of diagnosis of HNC or 
other cancers, death, 1 January 2009, emigration, or lost to 
follow-up, whichever came first. We used cumulative incidence 
function to illustrate time to first HNC, recognizing death and 
diagnoses of other cancers as a competing risk.17 Incidence rate 
ratios (IRR) and 95% confidence intervals (CI) for HNC were 
calculated using Cox proportional-hazards regression.
In order to identify risk factors for HNC in the HIV patient 
population, we calculated IRRs stratified by gender, race 
(Caucasian vs non-Caucasian), age at index date (#50 years 
vs .50 years), diagnosis of HIV before 1 January 1995, 
smoking (previous or current smoker in any quantity, never 
smoked, unknown smoking status), route of infection (men 
who have sex with men [MSM], heterosexually infected men 
and women, injection drug user [IDU]), AIDS-defining event 
at index date or prior to 1 January 1995 if diagnosed with 
HIV before 1 January 1995 (none vs $one) or low baseline 
CD4 cell count (,350 cells/µL vs $350 cells/µL). IRRs were 
calculated for both HNC cancers of squamous cell and other 
origin as well as for the HPV-related cancers, the potentially 
HPV-related cancers, and the potentially HPV-unrelated can-
cers. All results were adjusted for age (continuous variable) 
and gender. We calculated overall IRRs of HNC in the parent 
populations and IRRs stratified on the HIV infected offspring’s 
route of infection. IRRs for parent populations were adjusted 
for age at parent index date (continuous variable) as well as 
year of birth of the parent divided into the following decades: 
1920, 1920–1930, 1930–1940, 1940–1950, 1950 – later.
The study was approved by the Danish Data Protection 
Agency. SPSS statistical software, Version 15.0 (Norusis; 
SPSS Inc., Chicago, Illinois, USA) and R software, version 
2.8.1, was used for data analysis.
Results
In the first part of the study, we included a total of 5053 Danish 
HIV patients and 50,530 age- and gender-matched population 
controls with a total of 37,622 and 470,322 person-years of 
follow-up (Figure 1). Patient characteristics are described 
in Table 1.
A total of 333 (6.6%) HIV patients and 1328 (2.6%) popu-
lation controls were diagnosed with a cancer in the observation 
period and 25 and 83, respectively, were diagnosed with HNC. 
Among these HNCs we excluded seven lymphomas and one 
nonmicroscopically confirmed cancer in the HIV patients and 
one lymphoma and two nonmicroscopically confirmed cancer 
in the population controls, leaving a total of 17 (0.3%) and 
80 (0.2%) HNCs. Their characteristics are listed in Table 1. 
Fifteen (83%) HIV patients with HNC were   smokers. Nadir 
CD4 cell count in the HIV patients diagnosed with HNC was 
180 cells/µL (interquartile range [IQR] 36–253 cells/µL) 
and median CD4 cell count at time of cancer diagnosis was 
408 cells/µL (IQR 280–628 cells/µL).
As seen in Figure 2, the HIV patients had a .three times 
higher 10-year probability for HNC than the control popu-
lation. The IRR of HNC was three times higher for HIV 
patients (adjusted IRR 3.05 [95% CI 1.81–5.15]). The IRRs 
for HNC remained high in all stratified analyses (Table 2). 
The risk of HNC according to HPV-related sites differed 
little (Table 2).
We identified a total of 2317 fathers of HIV patients, 
30,886 fathers of population controls, 2502 mothers of HIV 
patients, and 31,928 mothers of population controls (Table 3). 
The 20-year probability of HNC was higher for both fathers 
and mothers of HIV patients   (Figure 3A, B). The adjusted 
IRR for HNC for fathers and mothers of HIV patients were 
1.78 (95% CI 1.28–2.48) and 2.43 (95% CI 1.51–3.92). After 
stratification on the children’s route of HIV infection, the rela-
tive risk remained high in all groups particularly for parents 
of MSMs (Table 4).
Discussion
We found a threefold increased risk of HNC in HIV 
patients compared with the background population. None 
of our stratified analyses identified a single risk factor 
which could explain the increased incidence of HNC in 
this patient population. Both fathers and mothers of HIV 
patients had an increased risk of HNC compared with 
the parents of the population controls. HIV appeared to 
be a marker of family-related factors that affect the risk 
of HNC.
To our knowledge this is the first nationwide study 
comparing the incidence of HNC in HIV patients with that 
of a matched control population and their parents. A major 
strength of the study is the quality and coverage of the Dan-
ish registries and the population-based design with long 
and nearly complete follow-up along with access to valid 
data on family members. Further we included only micro-
scopically confirmed HNCs, thereby eliminating the risk of 
misclassification.
We did not estimate the risk of HNC in relation to the 
implementation of HAART. However, the development of 
HNC presumably takes several years and it is therefore 
difficult to estimate the impact of risk factors that vary 
over time. Our registry data did not allow adjustment for Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of hiV patients and population controls with head and neck cancer
HIV patients,  
N (%)
Population  
controls,  
N (%)
HIV patients diagnosed  
with head and  
neck cancer, N (%)
Population controls  
diagnosed with head  
and neck cancer, N (%)
P value*
n 5053 50,530 17 80
Male gender 3827 (75.7) 38,270 (75.7) 13 (76) 77 (95) 0.004
Age at time of index date,  
median (iQr), years
36.6 (30.4–44.3) 36.6 (30.4–44.3) 50.90 (40.23–54.49) 47.18 (40.32–56.06) 0.809
Age at time of cancer  
diagnosis, median (iQr), years
– – 55.58 (48.62–61.90) 55.03 (48.63–62.54) 0.802
Older than 50 years  
at index date
695 (13.8) 6950 (13.8) 10 (59.0) 31 (38.8) 0.128
Caucasians 3976 (78.7) 16 (94.0)
route of hiV infection
  Men who have sex with men 2287 (45.3) 6 (35.0)
  heterosexually infected 1864 (36.9) 6 (35.0)
  injection drug user 553 (10.9) 3 (17.6)
  Other 349 (6.9) 2 (11.8)
One or more AIDS defining  
events prior to index date
719 (14.2) 3 (17.6)
Diagnosed with hiV before  
1 January 1995
1968 (38.9) 8 (47.1)
Current or previous smoker** 2600 (71.1) 15 (88.2)
never smoked*** 1058 (28.9) 2 (11.8)
Unknown smoking status 1395 (27.6) –
Baseline CD4 cell count,  
cells/µL, median (iQr)
279 (104–480) 309 (30–402)
HIV patients with head  
and neck cancer, N (%)
Population controls with  
head and neck cancer, N (%)
All head and neck cancers  
of squamous cell origin
16 (100) 70 (100)
HPV sites 6 (37.5) 16 (22.9)
  Tonsil and Waldeyers ring 3 (50.0) 12 (75.0)
  Tongue base and tonsil 1 (16.7) 1 (6.3)
  Other oro-pharynx 2 (33.3) 3 (18.8)
Potential HPV sites 7 (43.8) 42 (60.0)
  Tongue 1 (14.3) 4 (9.5)
  Other oral cavity sites 1 (14.3) 14 (33.3)
  Larynx 5 (71.4) 22 (52.4)
  Other oro-pharyngeal sites 0 (0) 2 (4.8)
Potentially unrelated to HPV 3 (18.8) 12 (17.1)
  remaining hnC sites 3 (18.8) 12 (17.1)
P value for difference in  
distribution of hPV site,  
potential hPV site and  
potentially unrelated hPV site
0.424
Note: *P value for differences between hiV patients diagnosed with head and neck cancer and population controls diagnosed with head and neck cancer. **2600 hiV patients 
were current or previous smokers out of 3658 hiV patients asked about smoking. ***1058 hiV patients had never smoked out of 3658 hiV patients asked about smoking.
Abbreviations: hPV, human papilloma virus; iQr, interquartile range.
potential effects of confounders, such as smoking and alcohol 
  consumption, and we had no data on HPV prevalence status 
or HPV status of the tumors. The few number of events did 
not allow us to perform complex multivariate analyses which 
is why we chose to use a stratified approach adjusted only 
for age and gender.
The epidemiology of HNC has changed during the 
last 40 years in the Western world. There has been an 
increase in the incidence rates of squamous cell HNCs at 
HPV-related and potentially HPV-related sites especially 
seen in men ,60 years, whereas the incidence rates of 
HNC at potentially HPV-unrelated sites have been stable.16,18 
The increase in HNC is seen in spite of unchanged alcohol 
consumption rates, increased vegetable and fruit intake, and a 
decreasing prevalence of smoking in the same period.19 These 
findings suggest that other etiological factors are involved. Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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A high prevalence of HPV DNA has been demonstrated 
in certain HNC tumors and high-risk types of HPV have 
been reported to be risk factors for several types of HNCs, 
perhaps due to changes in sexual behavior especially oral sex 
in the younger generations.20–23 Also, the prognosis is more 
favorable in HPV-positive HNCs, pointing towards a differ-
ent type of HNC than those related to alcohol and tobacco 
consumption.24,25
We found an excess risk of HNC in Danish HIV 
patients which is consistent with the findings of Silverberg 
et al who reported a relative risk of 2.0 for HPV-related 
HNCs and 2.7 for other HNCs in HIV patients.4 The rela-
tive risk of HNC was also high in younger HIV patients 
which is probably confounded by the larger prevalence of 
smoking compared with the background population. Also 
HIV patients diagnosed after 1995 were at higher risk. 
The reason could be that this patient group has a smaller 
degree of   immunodeficiency and competing HIV-related 
comorbidity due to larger availability of HAART, thereby 
allowing for the development of cancers that are more 
directly related to life style than immunodeficiency. More 
than 70% of the HIV patients were previous or current 
smokers and this group of HIV patients had an increased 
risk of HNC.
Studies investigating the association between HNC and 
sexual behaviors in persons without HIV found an increased 
risk of HNC in tonsils and base of tongue in gay men, possibly 
related to differences in sexual practices.26 In contrast, the 
population controls :10-year probability of neck and head cancer = 0.14 % (95% Cl; 0.11% - 0.18%)
:10-year probability of neck and head cancer = 0.29 % (95% Cl; 0.15% - 0.51%) HIV patients
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HIV infected MSMs in our study had a considerably lower and 
nonsignificant risk of HNC than the heterosexually infected 
HIV patients,   corresponding to the findings of Chaturvedi 
et al.27 This implies that risk factors other than sexual behavior 
are involved in HIV patients. The consumption of tobacco is 
higher in persons with lower socioeconomic status and the 
only study made on the subject in a European setting shows 
a lower socioeconomic status in heterosexually infected HIV 
patients than in MSMs.28 Therefore the differences could 
be due to differences in tobacco and alcohol consumption. 
Table 2 Stratified incidence rate ratios (IRRs) of head and neck cancer in HIV patients compared with population controls
HIV patients diagnosed  
with head and  
neck cancer, N
Population controls  
diagnosed with head  
and neck cancer, N
Unadjusted IRR 
(95% CI)
Adjusted IRR** 
(95% CI)
All 17 80 2.76 (1.64–4.67) 3.05 (1.81–5.15)
Stratified on risk factors*
Male gender** 13 77 2.26 (1.25–4.07) 2.47 (1.37–4.45)
Female gender 4 3 15.76 (3.52-70.58) ***
Caucasian 16 76 2.80 (1.63–4.80) 3.05 (1.78–5.23)
non-Caucasians 1 4 2.92 (0.33–26.13) ***
Younger than or 50 years at index date 7 49 1.89 (0.85–4.17) 1.92 (0.87–4.23)
Older than 50 years at index date** 10 31 4.50 (2.21–9.20) 4.58 (2.24–9.35)
hiV diagnosed before 1995 8 62 1.86 (0.89–3.89) 2.03 (0.97–4.23)
hiV diagnosed after 1995 at index date 9 18 5.55 (2.49–12.35) 6.31 (2.82–14.08)
Current or previous smoker**** 15 36 4.25 (2.33–7.75) 4.34 (2.43–8.09)
never smoked**** 2 10 1.98 (0.43–9.04) ***
route of hiV infection
  Men who have sex with men (MsM) 6 52 1.52 (0.65–3.54) 1.64 (0.70–3.82)
  heterosexually infected men 5 13 4.66 (1.66–13.10) 5.54 (1.96–15.66)
  heterosexually infected women 1 1 10.86 (0.68–173.30) **
  injection drug user (iDU) 3 8 6.95 (1.82–26.44) 7.82 (2.03–30.16)
Baseline CD4 , 350 cells/µL or  
AIDS defining event at index date
10 43 3.42 (1.71–6.81) 3.89 (1.95–7.78)
Baseline CD4 $ 350 cells/µL and  
no AIDS defining event at index date
7 37 2.16 (.96–4.85) 2.20 (0.97–4.93)
Head and neck cancer origin HIV patients diagnosed  
with head and neck  
cancer, N
Population controls  
diagnosed with head  
and neck cancer, N
Unadjusted IRR 
(95% CI) 
Adjusted IRR* 
(95% CI)  
Head and neck squamous cell cancers 16 70 2.96 (1.71–5.09) 2.96 (1.72–5.09)
rr for hPV-related hnC 6 16 4.66 (2.08–10.44) 5.10 (2.28–11.44)
rr for potentially hPV-related hnC 7 42 2.75 (1.51–5.01) 2.95 (1.62–5.37)
rr for potentially hPV-unrelated hnC 3 12 4.49 (1.90–10.64) 4.92 (2.07–11.66)
Notes: *In the stratified analyses HIV patients and their respective population controls were included; **all adjusted for gender and age, except the stratification on male 
which is only adjusted for age and age . 50 years which is only adjusted for gender; ***too few events for analysis; ****hiV patients (1395) and population controls (13,950) 
with missing data on smoking were excluded from this analysis.
Abbreviations: CI, confidence interval; HNC, head and neck cancer; HPV, human papilloma virus; RR, relative risk.
Table 3 Characteristics of parents of hiV patients and population controls
Fathers of HIV  
patients, N (%)
Fathers of population  
controls, N (%)
Mothers of HIV  
patients, N (%)
Mothers of population   
controls, N (%)
All 2317 30,886 2502 31,928
Median age at index date, years (iQr) 42.5 (40.0–50.1) 41.5 (40.0–49.0) 39.1 (32.8–46.0) 38.4 (32.3–45.2)
Follow-up time, median, years (iQr) 23.8 (16.4–30.0) 24.5 (18.0–30.1) 24.3 (17.5–30.3) 25.0 (18.9–30.8)
Duration of follow-up, person-years 50,937 703,036 56,538 746,786
Emigration during follow-up, n (%) 231 (10) 222 (0.7) 23 (0.9) 170 (0.5)
Lost to follow-up, n (%) 2 (0.1) 7 (0.0) 2 (0.1) 1 (0.0)
Diagnosed with all head and neck cancers, n (%) 40 (1.7) 309 (1.0) 20 (0.8) 108 (0.3)
Median age at diagnose of all head and  
neck cancers, years (iQr)
62.4 (54.5–68.9) 61.8 (55.6–68.0) 59.1 (53.5–61.1) 61.1 (54.4–67.7)
Abbreviation: iQr, interquartile range.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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:20-year probability of head and neck cancer = 0.66% (95% Cl; 0.57% - 0.75%)
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Figure 3 Cumulative incidence function for head and neck cancer among parents of hiV patients and parents of population controls.
Abbreviation: CI, confidence interval.
Table 4 Incidence rate ratios (IRRs, stratified by the offspring’s route of HIV infection) for head and neck cancer comparing the parents 
of hiV patients with the parents of the population controls
Parents of HIV patients  
diagnosed with head  
and neck cancer, N
Parents of population  
controls diagnosed with  
head and neck cancer, N
Unadjusted IRR 
(95% CI)
Adjusted IRR* 
(95% CI)
Fathers of hiV patients vs fathers  
of population controls
40 309 1.80 (1.30–2.50) 1.78 (1.28–2.48)
Stratification
route of hiV infection for offspring
  MsM 23 126 1.99 (1.28–3.11) 1.93 (1.24–3.01)
  heterosexually infected 6 101 1.17 (0.51–2.67) 1.16 (0.51–2.64)
  iDU 8 52 2.02 (0.96–4.26) 1.99 (0.94–4.20)
Mothers of hiV patients vs  
Mothers of population controls
20 108 2.47 (1.53–3.98) 2.43 (1.51–3.92)
route of hiV infection for offspring
  MsM 10 50 2.14 (1.08–4.21) 2.07 (1.05–4.09)
  heterosexually infected 2 35 1.06 (0.26–4.41) 1.03 (0.25–4.7)
  iDU 6 16 4.46 (1.79–11.66) 4.42 (1.73–11.35)
Notes: *Adjusted for age at parent index date (continuous variable) as well as year of birth of the parent divided into the following decades: –1920, 1920–1930, 1930–1940, 
1940–1950, 1950–later.
Abbreviations: CI, confidence interval; IDU, injection drug user; MSM, men who have sex with men.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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IDUs with HIV are known to smoke more and did also have 
an increased risk of lung cancer.29
The relative risk of HNC was high among both HIV 
patients with and without immunodeficiency at baseline 
but showed no significant difference. Notably the median 
CD4 cell count at the time of HNC diagnosis was high. This 
suggests that the increased risk is more likely related to tra-
ditional risk factors and there appears to be little association 
between immunodeficiency and HNC in Danish HIV patients. 
A   similar pattern is seen in cervix cancer in HIV infected 
women, whereas anal cancer is the only HPV-related cancer 
in HIV patients in whom a clear association between low CD4 
cell count and increased risk has been demonstrated.5,27,30
The relative risks of HNC in HIV patients stratified on 
HPV relation differed little, indicating that the impact of HPV 
is not higher in Danish HIV patients than in the background 
population and that risk factors other than immunodeficiency 
causes the excess risk. Still, we are reluctant to eliminate HIV 
infection as a direct biological risk factor for HNC, since we 
were not able to adjust these estimates directly for smoking, 
alcohol consumption, or HPV status, which are all potential 
serious confounders.
The risk of HNC was high also in both fathers and mothers 
of HIV patients, implying that family-associated or behavioral 
risk factors are involved. However, our study cannot identify the 
nature of the specific risk factors leading to the increased risk of 
HNC. Still, risk-taking behavior is moderately to strongly related 
to heritability and, for example, offspring of smokers have a 
4 times higher risk of initiating smoking.31,32 More than 70% of 
the patients in this HIV cohort were previous or current smokers 
and HIV patients are shown also to have an excess consumption 
of alcohol.33 It therefore seems likely that their parents share 
the same risk-taking behavior, which may explain a substantial 
part of the increased risk of HNC in both HIV patients and 
their parents. HIV therefore appears to be a marker of family-
related factors that affect the incidence of HNC. Unlike their 
offspring and parents of homosexually infected HIV patients, 
parents of heterosexually infected HIV patients did not have an 
excess risk of HNC. The effect was consistent for both parent 
populations, which indicates that this observation is valid. The 
reason for this is unclear, but the epidemiology of HNC has 
changed over recent decades and calendar effects may partly 
explain this phenomenon.
In conclusion both HIV patients and their parents have a 
high risk of HNC, suggesting that family-related risk factors 
explain part of the increased risk. None of our stratified or 
adjusted analyses isolated a single cause of the increased risk 
of HNC, but smoking, older age, and heterosexual route of 
infection was associated with an increased risk. HIV appears 
to be a marker of family-related factors associated with an 
increased risk of HNC.
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Appendix
Cancers included as competing risk in the study were coded 
according to The International Classification of Diseases 
(ICD) version 10 in the period 1978–2007: Lib cancer 
(ICD-10; C00), Tongue cancer (ICD-10; C01–C02), Oral 
cavity cancer (ICD-10; C03–C06), Salivary glands cancer 
(ICD-10; C07–C08), Tonsil cancer (ICD-10; C09), Pharynx 
cancer (1470–1480, ICD-10; C10–C14), Sinuses, nasal cavity 
and middle ear (ICD-10; C30), Larynx cancer (ICD-10; C32), 
Trachea cancer (2620, ICD-10; C33), Pleura cancer (ICD-10; 
C38.4, C45), Oesophagus, stomach and small intestine cancer 
(ICD-10; C15–C17), Colon cancer (ICD-10; C18–C20), 
Anal cancer (ICD-10; C21), Pancreas cancer (ICD-10; C25), 
Liver cancer (ICD-10; C22), Biliary tract cancer (ICD-10; 
C23, C24), Lymphoid cancer (ICD-10; C81–C85, C90–C96), 
Urinary tract cancers (ICD-10; C64–C68, D90, D414), 
Skin cancer (ICD-10; C43, C46), Bone, articular cartilage, 
mesothelial, and soft tissue cancer (ICD-10; C40, C41, C46.1 
C49), Breast cancer (ICD-10; C50), Female genital cancer 
(ICD-10; C51–C58), Eye, brain, and other parts of the central 
nervous system (ICD-10; C69–C72, D32, D34, D42, D43), 
Male genital organs (ICD-10; C60–C63), Thyroid and other 
endocrine organs (ICD-10; C73–C75), Kaposi sarcoma 
(ICD-10; C46).